L-Chicoric acid inhibits human immunodeficiency virus type 1 integration in vivo and is a noncompetitive but reversible inhibitor of HIV-1 integrase in vitro

Virology

Volumn 326, Issue 2, 2004, Pages 203-219

  Reinke, Ryan A ^a   Lee, Deborah J ^a   McDougall, Brenda R ^a   King, Peter J ^a   Victoria, Joseph ^a   Mao, Yingqun ^b   Lei, Xiangyang ^b   Reinecke, Manfred G ^b   Robinson Jr , W Edward ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b TEXAS CHRISTIAN UNIVERSITY   (United States)

Author keywords

Acquired immune deficiency syndrome; Biochemistry; Experimental therapeutics; Provirus; Real time polymerase chain reaction; Steady state kinetic analyses

Indexed keywords

CICHORIC ACID; INTEGRASE; VIRUS DNA; VIRUS ENZYME;

ARTICLE; CHROMOSOME; CONCENTRATION RESPONSE; CONTROLLED STUDY; COVALENT BOND; DRUG POTENCY; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR MECHANICS; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN INTERACTION; QUANTITATIVE ANALYSIS; STEADY STATE; VIRUS INHIBITION;

ACETOACETATES; BINDING SITES; CAFFEIC ACIDS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; ECHINACEA; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HIV-1; HUMANS; KINETICS; MUTATION; POLYMERASE CHAIN REACTION; PYRROLES; SUCCINATES; VIRUS INTEGRATION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 4043078554     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.virol.2004.06.005     Document Type: Article

References (90)

1. Abrams D., Cotton D., Markowitz M., Mayer M. AR-177 (Zintevir). AIDS/HIV Treatment Directory. vol. 8:1996;50-51 AmFAR, New York
2. Albrecht M.A., Bosch R.J., Hammer S.M., Liou S.-H., Kessler H., Para M.F., Eron J., Valdez H., Dehlinger M., Katzanstein M. Nelfinavir, Efavirenz, or both after the failure of nucleoside treatment of HIV infection. N. Engl. J. Med. 345:2001;398-407
3. Althaus I.W., Chou J.J., Gonzales A.J., Deibel M.R., Chou K.C., Kezdy F.J., Romero D.L., Aristoff P.A., Tarpley W.G., Reusser F. Steady-state kinetic studies with the non-nucleoside HIV-1 reverse transcriptase inhibitor U87201E. Experientia. 50:1993;23-28
4. Althaus I.W., Chou J.J., Gonzales A.J., Deibel M.R., Chou K.C., Kezdy F.J., Romero D.L., Palmer J.R., Thomas R.C., Aristoff P.A. Kinetic studies with the non-nucleoside HIV-1 reverse transcriptase inhibitor U88204E. Biochemistry. 32:1993;6548-6554
5. Autran B., Carcelain G., Li T.S., Blanc C., Mathez D., Tubiana R., Katlama C., Debre P., Leibowitch J. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science. 277:1997;112-116
6. Baldanti F., Paolucci S., Maserati R., Maggiolo F., Pan A., Castelli F., Gulminetti R., Comolli G., Chiesa A., Gerna G. Higher short-term virologic efficacy of three-class versus two-class highly active antiretroviral salvage therapy in HIV-infected patients. Eur. J. Clin. Microbiol. Infect. Dis. 19:2000;380-384
7. Beale K., Robinson W.E. Jr. Combinations of reverse transcriptase, protease, and integrase inhibitors can be synergistic in vitro against drug-sensitive and RT inhibitor-resistant molecular clones of HIV-1. Antiviral Res. 46:2000;223-232
8. Brown P.O., Bowerman B., Varmus H.E., Bishop J.M. Retroviral integration: structure of the initial covalent product and its precursor, and a role for the viral IN protein. Proc. Natl. Acad. Sci. U.S.A. 86:1989;2525-2529
9. Bugreev D.V., Baranova S., Zakharova O.D., Parissi V., Desjobert C., Sottofattori S., Balbi A., Litvak S., Tarrago-Litvak L., Nevinsky G.A. Dynamic, thermodynamic, and kinetic basis for recognition and transformation of DNA by human immunodeficiency virus type 1 integrase. Biochemistry. 42:2003;9235-9247
10. 14. Anales Asoc. Quim. Arg. 51:1963;330-332
11. Bujacz G., Alexandratos J., Zhou-Liu Q., Clement-Mella C., Wlodawer A. The catalytic domain of human immunodeficiency virus integrase: ordered active site in the F185H mutant. FEBS Lett. 398:1996;175-178
12. Bujacz G., Jaskolski M., Alexandratos J., Wlodawer A., Merkel G.M., Katz R.A., Skalka A.M. The catalytic domain of avian sarcoma virus integrase: conformation of the active-site residues in the presence of cations. Structure. 4:1996;89-96
13. Bushman F.D., Craigie R. Activities of human immunodeficiency virus (HIV) integration protein in vitro: specific cleavage and integration of HIV DNA. Proc. Natl. Acad. Sci. U.S.A. 88:1991;1339-1343
14. Butler S.L., Hansen M.S.T., Bushman F.D. A quantitative assay for HIV DNA integration in vivo. Nat. Med. 7:2001;631-634
15. 2+-dependent DNA integration in vitro. J. Virol. 71:1997;6225-6229
16. Charlton J.L. Antiviral activity of lignans. J. Nat. Prod. 61:1998;1447-1451
17. Chow S.A. In vitro assays for activities of retroviral integrase. Methods: A Companion to Methods in Enzymology. vol. 12:1997;306-317
18. Chow S.A., Brown P.O. Substrate features important for recognition and catalysis by human immunodeficiency virus type 1 integrase identified by using novel DNA substrates. J. Virol. 68:1994;3896-3907
19. Chow S.A., Vincent K.A., Ellison V., Brown P.O. Reversal of integration and DNA splicing mediated by integrase of human immunodeficiency virus. Science. 255:1992;723-726
20. Collier A.C., Coombs R.W., Schoenfeld D.A., Bassett R.L., Timpone J., Baruch A., Jones M., Facey K., Whitacre C., McAuliffe V.J., Friedman H.M., Merigan T.C., Reichman R.C., Hooper C., Corey L. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. N. Engl. J. Med. 334:1996;1011-1017
21. Condra J.H., Schleif W.A., Blahy O.M., Gabryelski L.J., Graham D.J., Quintero J.C., Rhodes A., Robbins H.L., Roth E., Shivaprakash M., Titus D., Yang T., Teppler H., Squires K.E., Deutsch P.J., Emini E.A. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature. 374:1995;569-571
22. Conway B., Wainberg M.A., Hall D., Harris M., Reiss P., Cooper D., Vella S., Curry R., Robinson P., Lange J.M., Montaner J.S.G. Development of drug resistance in patients receiving combinations of zidovudine, didanosine, and nevirapine. AIDS. 15:2001;1269-1274
23. Daniel R., Katz R.A., Skalka A.M. A role for DNA-PK in retroviral DNA integration. Science. 284:1999;644-647
24. DeVoss J.J., Sui Z., DeCamp D.L., Salto R., Babe L.M., Craik C.S., Ortiz de Montellano P.R. Haloperidol-based irreversible inhibitors of the HIV-1 and HIV-2 proteases. J. Med. Chem. 37:1994;665-673
25. Dotan I., Scottoline B.P., Heuer T.S., Brown P.O. Characterization of recombinant murine leukemia virus integrase. J. Virol. 69:1995;456-468
26. Engelman A., Craigie R. Identification of conserved amino acid residues critical for human immunodeficiency virus type 1 integrase function in vitro. J. Virol. 66:1992;6361-6369
27. Engelman A., Liu Y., Chen H., Farzan M., Dyda F. Structure-based mutagenesis of the catalytic domain of human immunodeficiency virus type 1 integrase. J. Virol. 71:1997;3507-3514
28. Espeseth A.S., Felock P., Wolfe A., Witmer M., Grobler J., Anthony N., Egbertson M., Melamed J.Y., Young S., Hamill T., Cole J.L., Hazuda D.J. HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase. Proc. Natl. Acad. Sci. U.S.A. 97:2000;11244-11249
29. Farnet C.M., Wang B., Hansen M., Lipford J.R., Zalkow L., Robinson W.E. Jr., Siegel J., Bushman F. Human immunodeficiency virus type 1 cDNA integration: new aromatic hydroxylated inhibitors and studies of the inhibition mechanism. Antimicrob. Agents Chemother. 42:1998;2245-2253
30. Fujiwara T., Mizuuchi K. Retroviral DNA integration: structure of an integration intermediate. Cell. 54:1988;497-504
31. Furfine E.S., D'Souza E., Ingold K.J., Leban J.J., Spector T., Porter D.J. Two-step binding mechanism for HIV protease inhibitors. Biochemistry. 31:1992;7886-7891
32. Gao Q., Gu Z., Parniak M.A., Cameron J., Cammack N., Boucher C., Wainberg M.A. The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2′,3′-dideoxyinosine and 2′,3′- dideoxycytidine confers high-level resistance to the (-) enantiomer of 2′,3′-dideoxy-3′-thiacytidine. Antimicrob. Agents Chemother. 37:1993;1390-1392
33. Goldgur Y., Dyda F., Hickman A.B., Jenkins T.M., Craigie R., Davies D.R. Three new structures of the core domain of HIV-1 integrase: an active site that binds magnesium. Proc. Natl. Acad. Sci. U.S.A. 95:1998;9150-9154
34. Gu Z., Gao Q., Li X., Parniak M.A., Wainberg M.A. Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2′,3′-dideoxyinosine and 2′,3′- dideoxycytidine. J. Virol. 66:1992;7128-7135
35. Gu Z., Gao Q., Fang H., Parniak M.A., Brenner B.G., Wainberg M.A. Identification of novel mutations that confer drug resistance in the human immunodeficiency virus polymerase gene. Leukemia. 8(Suppl. 1):1994;S166-S169
36. Gulnik S.V., Suvorov L.I., Liu B., Yu B., Anderson B., Mitsuya H., Erickson J.W. Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure. Biochemistry. 34:1995;9282-9287
37. Gulick R.M., Mellors J.W., Havlir D., Eron J.J., Gonzalez C., McMahon D., Richman D.D., Valentine F.T., Jonas L., Meibohm A., Emini E.A., Chodakewitz J.A. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N. Engl. J. Med. 337:1997;734-739
38. Hazuda D.J., Felock P.J., Hastings J.C., Pramanik B., Wolfe A.L. Differential divalent cation requirements uncouple the assembly and catalytic reactions of human immunodeficiency virus type 1 integrase. J. Virol. 71:1997;7005-7011
39. Hazuda D.J., Pelock P., Witmer M., Wolfe A., Stillmock K., Grobler J.A., Espeseth A., Gabryelski L., Schleif W., Blau C., Miller M.D. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science. 287:2000;646-650
40. Hecht F., Grant R., Petropoulos C., Dillon B., Chesney M., Tian H., Hellmann N., Brandrapalli N., Digilio L., Branson B., Kahn J. Sexual transmission of an HIV-1 variant resistant to multiple reverse transcriptase and protease inhibitors. N. Engl. J. Med. 339:1998;307-311
41. Jones K.S., Coleman J., Merkel G.W., Laue T.M., Skalka A.M. Retroviral integrase functions as a multimer and can turn over catalytically. J. Biol. Chem. 267:1992;16037-16040
42. Kellogg D.E., Kwok S. Detection of human immunodeficiency virus. Innis M.A., Gelfand D.H., Sninsky J.J., White T.J. PCR Protocols: a Guide to Methods and Applications. 1990;337-347 Academic Press, San Diego
43. King P.J., Robinson W.E. Jr. Resistance to the anti-human immunodeficiency virus type 1 compound L-chicoric acid results from a single mutation at amino acid 140 of integrase. J. Virol. 72:1998;8420-8424
44. King P.J., Ma G., Miao W., Jia Q., McDougall B.R., Reinecke M.G., Cornell C., Kuan J., Kim T.R., Robinson W.E. Jr. Structure-activity relationships: analogues of the dicaffeoylquinic and dicaffeoyltartaric acids as potent inhibitors of human immunodeficiency virus type 1 integrase and replication. J. Med. Chem. 42:1999;497-509
45. King P.J., Lee D.J., Reinke R.A., Victoria J.G., Beale K., Robinson W.E. Jr. Human immunodeficiency virus type 1 integrase containing a glycine to serine mutation at position 140 is attenuated for catalysis and resistant to integrase inhibitors. Virology. 306:2003;147-161
46. LaFemina R.L., Schneider C.L., Robbins H.L., Callahan P.L., LeGrow K., Roth E., Schleif W.A., Emini E.A. Requirement of active human immunodeficiency virus type 1 integrase enzyme for productive infection of human T-lymphoid cells. J. Virol. 66:1992;7414-7419
47. 2+-dependent 3′-processing activity of human immunodeficiency virus type 1 integrase in vitro. Biochemistry. 35:1996;3837-3844
48. Lee D.J., Robinson W.E. Jr. Human immunodeficiency virus type 1 (HIV-1) integrase: resistance to diketoacid integrase inhibitors impairs HIV-1 replication, integration, and confers cross-resistance to L-chicoric acid. J. Virol. 78:2004;5835-5847
49. Lee S.P., Kim H.G., Censullo M.L., Han M.K. Characterization of Mg(2+)-dependent 3′-processing activity for human immunodeficiency virus type 1 integrase in vitro: real-time kinetic studies using fluorescence resonance energy transfer. Biochemistry. 34:1995;10205-10214
50. Li L., Olvera J.M., Yoder K.E., Mitchell R.S., Butler S.L., Lieber M., Martin S.L., Bushman F.D. Role of the non-homologous DNA end joining pathway in the early steps of retroviral infection. EMBO J. 20:2001;3272-3281
51. Lin Y., Lin X., Hong L., Foundling S., Heinrikson R.L., Thaisrivongs S., Leelamanit W., Raterman D., Shah M., Dunn B.M., Tang J. Effect of point mutations on the kinetics and the inhibition of human immunodeficiency virus type 1 protease: relationship to drug resistance. Biochemistry. 34:1995;1143-1152
52. Lin Z., Neamati N., Zhao H., Kiryu Y., Turpin J.A., Aberham C., Strebel K., Kohn K., Witvrouw M., Pannecouque C., Debyser Z., DeClercq E., Rice W.G., Pommier Y., Burke T.R. Jr. Chicoric acid analogues as HIV-1 integrase inhibitors. J. Med. Chem. 42:1999;1401-1414
53. Marchand C., Johnson A.A., Karki R.G., Pais G.C.G., Zhang X., Cowansage K., Patel T.A., Nicklaus M.C., Burke T.R. Jr., Pommier Y. Metal-dependent inhibition of HIV-1 integrase by b-diketo acids and resistance of the soluble double-mutant (F185K/C280S). Mol. Pharmacol. 64:2003;600-609
54. McDougall B., King P.J., Wu B.W., Hostomsky Z., Reinecke M.G., Robinson W.E. Jr. Dicaffeoylquinic and dicaffeoyltartaric acids are selective inhibitors of human immunodeficiency virus type 1 integrase. Antimicrob. Agents Chemother. 42:1998;140-146
55. Miller M.D., Wang B., Bushman F.D. Human immunodeficiency virus type 1 preintegration complexes containing discontinuous plus strands are competent to integrate in vitro. J. Virol. 69:1995;3938-3944
56. Montaner J.S.G., Mellors J.W. Antiretroviral therapy for previously treated patients. N. Engl. J. Med. 345:2001;452-454
57. O'Doherty U., Swiggard W.J., Jeyakumar D., McGain D., Malim M.H. A sensitive, quantitative assay for human immunodeficiency virus type 1 integration. J. Virol. 76:2002;10942-10950
58. Ojwang J., Elbaggari A., Marshall H.B., Jayaraman K., McGrath M.S., Rando R.F. Inhibition of human immunodeficiency virus type 1 activity in vitro by oligonucleotides composed entirely by guanosine and thymidine. J. Acquired Immune Defic. Syndr. 7:1994;560-670
59. Ojwang J.O., Buckheit R.W., Pommier Y., Mazumder A., deVreese K., Este J.A., Reymen D., Pallansch L.A., Lackman-Smith C., Wallace T.L., deClercq E., McGrath M.S., Rando R.F. T30177, an oligonucleotide stabilized by an intramolecular guanosine octet, is a potent inhibitor of laboratory strains and clinical isolates of human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 39:1995;2426-2435
60. Pargellis C.A., Morelock M.M., Graham E.T., Kinkade P., Pav S., Lubbe K., Lamarre D., Anderson P.C. Determination of kinetic rate constants for the binding of inhibitors to HIV-1 protease and for the association and dissociation of active homodimer. Biochemistry. 33:1994;12527-12534
61. Pluymers W., Neamati N., Pannecouque C., Fikkert V., Marchand C., Burke T.R. Jr., Pommier Y., Schols D., De Clercq E., Debyser Z., Witvrouw M. Viral entry as the primary target for the anti-HIV activity of chicoric acid and its tetra-acetyl esters. Mol. Pharmacol. 58:2000;641-648
62. Pommier Y., Neamati N. Inhibitors of human immunodeficiency virus integrase. Adv. Virus Res. 52:1999;427-458
63. Reinke R., Steffen N.R., Robinson W.E. Jr. Natural selection results in conservation of HIV-1 integrase activity despite sequence variability. AIDS. 15:2001;823-830
64. Reinke R.A., King P.J., Victoria J.G., McDougall B.R., Ma G., Mao Y., Reinecke M.G., Robinson W.E. Jr. Dicaffeoyltartaric acid analogues inhibit human immunodeficiency virus type 1 (HIV-1) integrase and HIV-1 replication at non-toxic concentrations. J. Med. Chem. 45:2002;3669-3683
65. Robinson W.E. Jr. HIV integrase: the next target? Infect. Med. 15:1998;129-137
66. Robinson W.E. Jr. L-Chicoric acid, an inhibitor of human immunodeficiency virus type 1 (HIV-1) integrase, improves on the in vitro anti-HIV-1 effect of zidovudine plus a protease inhibitor (AG1350). Antiviral Res. 39:1998;101-111
67. Robinson W.E. Jr., Montefiori D.C., Gillespie D.H., Mitchell W.M. Complement-mediated, antibody-dependent enhancement of HIV-1 infection in vitro is characterized by increased protein and RNA syntheses and infectious virus release. J. Acquired Immune Defic. Syndr. 2:1989;33-42
68. Robinson W.E. Jr., Cordeiro M., Abdel-Malek S., Jia Q., Chow S.A., Reinecke M.G., Mitchell W.M. Dicaffeoylquinic acid inhibitors of human immunodeficiency virus integrase: inhibition of the core catalytic domain of human immunodeficiency virus integrase. Mol. Pharmacol. 50:1996;846-855
69. Robinson W.E. Jr., Reinecke M.G., Abdel-Malek S., Jia Q., Chow S.A. Inhibitors of HIV-1 replication that inhibit HIV integrase. Proc. Natl. Acad. Sci. U.S.A. 93:1996;6326-6331
70. Roth M.J., Schwartzberg P., Tanese N., Goff S.P. Analysis of mutations in the integration function of Moloney murine leukemia virus: effect on DNA binding and cutting. J. Virol. 64:1990;4709-4717
71. Sakai H., Kawamura M., Sakuragi J., Sakuragi S., Shibata R., Ishimoto A., Ono N., Ueda S., Adachi A. Integration is essential for efficient gene expression of human immunodeficiency virus type 1. J. Virol. 67:1993;1169-1174
72. Salto R., Babé L.M., Li J., Rosé J.R., Yu Z., Burlingame A., De Voss J.J., Sui Z., Ortiz de Montellano P., Craik C.S. In vitro characterization of nonpeptide irreversible inhibitors of HIV proteases. J. Biol. Chem. 269:1994;10691-10698
73. Selnick H.G., Hazuda D.J., Egbertson M., Guare J.P. Jr., Wai J.S., Young S.D., Clark D.L., Medina J.C. Int. Patent Application WO9962513. Chem. Abstr. 132:1999;22866
74. Sherman P.A., Fyfe J.A. Human immunodeficiency virus integration protein expressed in Escherichia coli possesses selective DNA cleaving activity. Proc. Natl. Acad. Sci. U.S.A. 87:1990;5119-5123
75. Sherman P.A., Dickson M.L., Fyfe J.A. Human immunodeficiency virus type 1 integration protein: DNA sequence requirements for cleaving and joining reactions. J. Virol. 66:1992;3593-3601
76. Stevenson M., Haggerty S., Lamonica C.A., Meier C.M., Welch S.K., Wasiak A.J. Integration is not necessary for expression of human immunodeficiency virus type 1 protein products. J. Virol. 64:1990;2421-2425
77. Swanstrom R. Characterization of HIV-1 protease mutants: random, directed, selected. Curr. Opin. Biotechnol. 5:1994;409-413
78. Tisdale M., Myers R.E., Maschera B., Parry N.R., Oliver N.M., Blair E.D. Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors. Antimicrob. Agents Chemother. 39:1995;1704-1710
79. Tramontano E., Colla P., Cheng Y. Biochemical characterization of the HIV-1 integrase 3′-processing activity and its inhibition by phosphorothioate oligonucleotides. Biochemistry. 37:1998;7237-7243
80. UK Collaborative Group on Monitoring the Transmission of HIV Drug Resistance Analysis of prevalence of HIV-1 drug resistance in primary infections in the United Kingdom. Br. Med. J. 322:2001;1087-1088
81. van Gent D.C., Elgersma Y., Bolk M.W., Vink C., Plasterk R.H. DNA binding properties of the integrase proteins of human immunodeficiency viruses types 1 and 2. Nucleic Acids Res. 19:1991;3821-3827
82. Victoria J.G., Lee D.J., McDougall B.R., Robinson W.E. Jr. Replication kinetics for divergent type 1 human immunodeficiency viruses using quantitative SYBR green I real-time polymerase chain reaction. AIDS Res. Hum. Retroviruses. 19:2003;865-874
83. Vincent K.A., Ellison V., Chow S.A., Brown P.O. Characterization of human immunodeficiency virus type 1 integrase expressed in Escherichia coli and analysis of variants with amino-terminal mutations. J. Virol. 67:1993;425-437
84. Wegner S.A., Brodine S.K., Mascola J.R., Tasker S.A., Shaffer R.A., Starkey M.J., Barile A., Martin G.J., Aronson N., Emmons W.W., Stephan K., Bloor S., Vingerhoets J., Hertogs K., Larder B. Prevalence of genotypic and phenotypic resistance to anti-retroviral drugs in a cohort of therapy-naive HIV-1 infected US military personnel. AIDS. 14:2000;1009-1015
85. Williams J.W., Morrison J.F. The kinetics of reversible tight-binding inhibition. Methods Enzymol. 63:1979;437-467
86. Wiskerchen M., Muesing M.A. Human immunodeficiency virus type 1 integrase: effects of mutations on viral ability to integrate, direct viral gene expression from unintegrated viral DNA templates, and sustain viral propagation in primary cells. J. Virol. 69:1995;376-386
87. Wu X., Liu H., Xiao H., Conway J.A., Hehl E., Kalpana G.V., Prasad V., Kappes J.C. Human immunodeficiency virus type 1 integrase protein promotes reverse transcription through specific interactions with the nucleoprotein reverse transcriptase complex. J. Virol. 73:1999;2126-2135
88. Young B., Johnson S., Bahktiari M., Shugarts D., Young R., Allen M., Ramey R., Kurutzkes D. Resistance mutations on protease and reverse transcriptase genes of human immunodeficiency virus type-1 isolates from patients with combination antiretroviral therapy failure. J. Infect. Dis. 178:1998;1497-1501
89. Zack J.A., Arrigo S.J., Weitsman S.R., Go A.S., Haislip A., Chen I.S.Y. HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell. 61:1990;213-222
90. Zhu K., Cordeiro M.L., Atienza J., Robinson W.E. Jr., Chow S.A. Irreversible inhibition of human immunodeficiency virus type 1 integrase by dicaffeoylquinic acids. J. Virol. 73:1999;3309-3316